

1. IMPORTANT NOTICE

- 1.1 The board of directors (the “Board”) and the supervisory committee (the “Supervisory Committee”) of the Company, in accordance with the provisions of the Company’s Articles of Association and the Company’s Regulations, have held the 2019 Third Quarter Report Review Meeting. The meeting discussed and approved the Company’s 2019 Third Quarter Report, which is hereby published. The Company’s 2019 Third Quarter Report is available on the Company’s website (www.1000000000.com) and the Shanghai Stock Exchange website (www.sse.com.cn). The Company’s 2019 Third Quarter Report is also available in printed form upon request.
- 1.2 A special meeting of the Board was held on November 1, 2019, to discuss and approve the Company’s 2019 Third Quarter Report. The meeting discussed and approved the Company’s 2019 Third Quarter Report, which is hereby published. The Company’s 2019 Third Quarter Report is available on the Company’s website (www.1000000000.com) and the Shanghai Stock Exchange website (www.sse.com.cn). The Company’s 2019 Third Quarter Report is also available in printed form upon request.
- 1.3 The Company’s 2019 Third Quarter Report is available on the Company’s website (www.1000000000.com) and the Shanghai Stock Exchange website (www.sse.com.cn). The Company’s 2019 Third Quarter Report is also available in printed form upon request. The Company’s 2019 Third Quarter Report is available on the Company’s website (www.1000000000.com) and the Shanghai Stock Exchange website (www.sse.com.cn). The Company’s 2019 Third Quarter Report is also available in printed form upon request.
- 1.4 The Company’s 2019 Third Quarter Report is available on the Company’s website (www.1000000000.com) and the Shanghai Stock Exchange website (www.sse.com.cn). The Company’s 2019 Third Quarter Report is also available in printed form upon request.

2. MAJOR FINANCIAL INFORMATION AND CHANGES IN SHAREHOLDERS OF THE GROUP

2.1 Major financial information

Unit: million RMB

	30 September 2019	31 December 2018	Ratio of change (%)
Total assets	78,569,297,725.65	70,551,361,387.48	11.36
Non-current assets	30,633,746,877.27	27,977,736,427.49	9.49
	Jan – Sept 2019	Jan – Sept 2018	Period-on-period change (%)
Non-current assets	2,328,355,784.17	2,087,826,458.74	11.52
	Jan – Sept 2019	Jan – Sept 2018	Period-on-period change (%)
Operating results	21,227,618,679.11	18,142,384,871.95	17.01
Non-current assets	2,063,704,147.99	2,094,152,353.81	-1.45
Non-current assets	1,722,388,028.34	1,591,668,096.39	8.21
Profit margin (%)	7.21	8.00	Decrease 0.79 percentage points
Basic earnings per share (RMB)	0.81	0.83	-2.41
Diluted earnings per share (RMB)	0.81	0.83	-2.41

Note: In the first nine months of 2019, the Group's total assets increased by RMB78,569.29772565 billion (or 11.36%) compared with the end of 2018. The Group's non-current assets increased by RMB30,633.74687727 billion (or 9.49%) compared with the end of 2018. The Group's operating results increased by RMB21,227.61867911 billion (or 17.01%) compared with the first nine months of 2018. The Group's non-current assets increased by RMB2,063.70414799 billion (or -1.45%) compared with the first nine months of 2018. The Group's non-current assets increased by RMB1,722.38802834 billion (or 8.21%) compared with the first nine months of 2018. The Group's profit margin decreased by 0.79 percentage points compared with the first nine months of 2018. The Group's basic earnings per share decreased by RMB0.02 compared with the first nine months of 2018. The Group's diluted earnings per share decreased by RMB0.02 compared with the first nine months of 2018.

The Group's total assets increased by RMB78,569.29772565 billion (or 11.36%) compared with the end of 2018. The Group's non-current assets increased by RMB30,633.74687727 billion (or 9.49%) compared with the end of 2018. The Group's operating results increased by RMB21,227.61867911 billion (or 17.01%) compared with the first nine months of 2018. The Group's non-current assets increased by RMB2,063.70414799 billion (or -1.45%) compared with the first nine months of 2018. The Group's non-current assets increased by RMB1,722.38802834 billion (or 8.21%) compared with the first nine months of 2018. The Group's profit margin decreased by 0.79 percentage points compared with the first nine months of 2018. The Group's basic earnings per share decreased by RMB0.02 compared with the first nine months of 2018. The Group's diluted earnings per share decreased by RMB0.02 compared with the first nine months of 2018.

The Group's total assets increased by RMB78,569.29772565 billion (or 11.36%) compared with the end of 2018. The Group's non-current assets increased by RMB30,633.74687727 billion (or 9.49%) compared with the end of 2018. The Group's operating results increased by RMB21,227.61867911 billion (or 17.01%) compared with the first nine months of 2018. The Group's non-current assets increased by RMB2,063.70414799 billion (or -1.45%) compared with the first nine months of 2018. The Group's non-current assets increased by RMB1,722.38802834 billion (or 8.21%) compared with the first nine months of 2018. The Group's profit margin decreased by 0.79 percentage points compared with the first nine months of 2018. The Group's basic earnings per share decreased by RMB0.02 compared with the first nine months of 2018. The Group's diluted earnings per share decreased by RMB0.02 compared with the first nine months of 2018.

The Group's total assets increased by RMB78,569.29772565 billion (or 11.36%) compared with the end of 2018. The Group's non-current assets increased by RMB30,633.74687727 billion (or 9.49%) compared with the end of 2018. The Group's operating results increased by RMB21,227.61867911 billion (or 17.01%) compared with the first nine months of 2018. The Group's non-current assets increased by RMB2,063.70414799 billion (or -1.45%) compared with the first nine months of 2018. The Group's non-current assets increased by RMB1,722.38802834 billion (or 8.21%) compared with the first nine months of 2018. The Group's profit margin decreased by 0.79 percentage points compared with the first nine months of 2018. The Group's basic earnings per share decreased by RMB0.02 compared with the first nine months of 2018. The Group's diluted earnings per share decreased by RMB0.02 compared with the first nine months of 2018.

2.2 The Company's shareholding status of the Top 10 shareholders at the end of the period is as follows:

The shareholding status of the Top 10 shareholders						Name of shareholders	Shareholding at the end of the period

--

The shareholding status of the Top 10 unrestricted shareholders			
Name of the shareholders	Number of unrestricted tradable shares held	Type and number of shares	
		Type	Number
SHANGHAI FOSUN HIGH TECHNOLOGY (GROUP) COMPANY LIMITED*	938,095,290	RMB ordinary shares	938,095,290
HKSCC NOMINEES LIMITED (Note 1)	551,255,448	Ordinary shares	551,255,448
CHINA SECURITIES FINANCE CORPORATION LIMITED*	38,736,157	RMB ordinary shares	38,736,157
HONG KONG SECURITIES CLEARING COMPANY LIMITED (Note 2)	36,199,707	RMB ordinary shares	36,199,707
NATIONAL SOCIAL SECURITY FUND 113 PORTFOLIO*	28,066,210	RMB ordinary shares	28,066,210
BASIC PENSION INSURANCE FUND 802 PORTFOLIO*	25,824,892	RMB ordinary shares	25,824,892
CENTRAL HUIJIN ASSET MANAGEMENT LTD.*	24,067,700	RMB ordinary shares	24,067,700
NATIONAL SOCIAL SECURITY FUND 110 PORTFOLIO*	15,358,518	RMB ordinary shares	15,358,518
ABU DHABI INVESTMENT AUTHORITY	13,790,532	RMB ordinary shares	13,790,532
CHINA CONSTRUCTION BANK CORPORATION—CHINA-EUROPEAL ENERGY EQUITY SECURITIES INVESTMENT FUND*	10,198,273	RMB ordinary shares	10,198,273
Disputed shares held by the company	1,370,000	Disputed shares held by the company	1,370,000
Disputed shares held by the company	1,370,000	Disputed shares held by the company	1,370,000

Note 1: HKSCC NOMINEES LIMITED, a wholly-owned subsidiary of HSBC Bank (China) Limited, holds 551,255,448 ordinary shares of the Company, representing 58.93% of the total shares of the Company. The shares are held in the name of HKSCC NOMINEES LIMITED, which is a nominee of HSBC Bank (China) Limited. The shares are held in the name of HKSCC NOMINEES LIMITED, which is a nominee of HSBC Bank (China) Limited. The shares are held in the name of HKSCC NOMINEES LIMITED, which is a nominee of HSBC Bank (China) Limited.

Note 2: HONG KONG SECURITIES CLEARING COMPANY LIMITED holds 36,199,707 ordinary shares of the Company, representing 3.85% of the total shares of the Company. The shares are held in the name of HONG KONG SECURITIES CLEARING COMPANY LIMITED, which is a nominee of HSBC Bank (China) Limited.

2.3 The company has no other shareholders holding 1% or more of the total shares of the Company. The company has no other shareholders holding 1% or more of the total shares of the Company. The company has no other shareholders holding 1% or more of the total shares of the Company.

Note: b

3. SIGNIFICANT EVENTS

[illegible]

(1) B \rightarrow S

: 1,000 CNY/USD: RMB

[illegible]

(3) S $\xrightarrow{\text{H}_2\text{SO}_4}$ C $\xrightarrow{\text{H}_2\text{SO}_4}$ F.

: 1,000 CNY : RMB

Statement of Cash Flow				
Items	Jan – Sept 2019	Jan – Sept 2018	Ratio of change	Reasons of changes
Net cash generated from operating activities	-2,560,243,375.55	-4,338,289,449.60	40.98%	Management has improved the efficiency of the business operation, and the cash flow has increased. SHL has received CMF from the government. The cash flow has increased.
Net cash used in investing activities	47,762,255.60	-31,014,791.25	254.00%	Management has increased the investment in the business operation. The cash flow has increased.

3.2 Assessment of the impact of the SS, the SS, and the SS on the SS

1. T, 2016 ... C ... s ... s ...
 ... SS! ... b ... s ... s ...
 ... C ... 's SS! ... s ... b ... s ...
 ... RMB10 b ... T ... N ... s ... A ... R ... s ... (... S ...
 ... 2018 MTN N. 208 ... S ... 2018 SCP N. 90) ... SS! ... b ...
 ... N ... Ass ... F ... M ... I s ... I s ... s ... 17 A ... 2018, ... s ...
 ... C ... 's ... s ... - ... s ... s ... S ...
 ... s ... s ... RMB5 b ... s ... T ... s ...
 ... 2 ... s ... s ... b ... SS! ... s ... s ... M ...
 ... s ... SS! ... S ... - ... s ...

T. SSI (G. L.) C., L. 2019 s. b. C. 29 Ju. 2019
 RMB300 3.00%.

2. O-19S_b 2019, C_b FSI H T, FSI H T (/ b s)
C (A
/ H s) S S S E ()
S -H K S C) 19 S_b 2019 18 S_b 2020,
RMB100
T s s s
2% ss s C s 19 S_b 2019 (. . 2,562,898,545 s ,
s b) (b s s C b
12- s 2% ss s C).

As of December 31, 2018, Fosun Pharmaceutical (Group) Co., Ltd. held 2,560,000 H shares of Shanghai Henlius Biotech, Inc. (Shanghai Henlius) at a cost of RMB53.54 per share. The total cost of the shares held by Fosun Pharmaceutical (Group) Co., Ltd. as of December 31, 2018 was RMB137,043,200. The cost of the shares held by Fosun Pharmaceutical (Group) Co., Ltd. as of December 31, 2019 was RMB137,043,200, which is an increase of 0.10% compared to the cost of the shares held by Fosun Pharmaceutical (Group) Co., Ltd. as of December 31, 2018.

3. On November 27, 2018, Shanghai Henlius Biotech, Inc. (Shanghai Henlius) issued 1,000,000 H shares at a price of HK\$49.60 per share. The total amount of the shares issued was HK\$49,600,000. The shares were listed on the Hong Kong Stock Exchange (Hong Kong Stock Exchange) on December 10, 2018.

On December 25, 2019, Shanghai Henlius Biotech, Inc. issued 1,000,000 H shares at a price of HK\$49.60 per share. The total amount of the shares issued was HK\$49,600,000. The shares were listed on the Hong Kong Stock Exchange (Hong Kong Stock Exchange) on January 2, 2020. The cost of the shares held by Fosun Pharmaceutical (Group) Co., Ltd. as of December 31, 2019 was RMB137,043,200, which is an increase of 53.76% compared to the cost of the shares held by Fosun Pharmaceutical (Group) Co., Ltd. as of December 31, 2018.

On October 17, 2019, Shanghai Henlius Biotech, Inc. issued 1,000,000 H shares at a price of HK\$49.60 per share. The total amount of the shares issued was HK\$49,600,000. The shares were listed on the Hong Kong Stock Exchange (Hong Kong Stock Exchange) on November 1, 2019. The cost of the shares held by Fosun Pharmaceutical (Group) Co., Ltd. as of December 31, 2019 was RMB137,043,200, which is an increase of 53.33% compared to the cost of the shares held by Fosun Pharmaceutical (Group) Co., Ltd. as of December 31, 2018.

3.3 Fosun Pharmaceutical (Group) Co., Ltd. held shares of Shanghai Henlius Biotech, Inc.

N/A

3.4 Fosun Pharmaceutical (Group) Co., Ltd. held shares of Shanghai Henlius Biotech, Inc.

N/A

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Legal Representative: Chen Qiyu

29 October 2019

4. APPENDICES

4.1 Financial statements

Consolidated balance sheet

30 September 2019

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Unit: million RMB Yuan (除特别说明外，均以人民币百万元表示)

Items	30 September 2019	31 December 2018
Current assets:		
Cash and cash equivalents	10,307,237,302.85	8,546,521,777.04
Financial assets at fair value through profit or loss	1,344,673,568.10	616,123,764.39
Receivables	258,620,513.78	712,510,581.95
Prepaid expenses	4,463,034,533.86	3,623,640,740.82
Other receivables	471,597,865.70	—
Inventory	596,927,301.93	472,144,580.30
Other current assets	577,591,869.92	447,434,579.55
Intangible assets	9,995,755.01	11,660,016.68
Deferred tax assets	36,917,475.21	19,731,451.25
Investments in subsidiaries	3,858,842,830.18	3,287,392,199.46
Non-current financial assets	—	—
Assets held for sale	1,162,820,637.56	—
Other non-current assets	368,970,686.90	295,958,970.62
Total current assets	23,410,317,110.78	18,001,727,194.13
Non-current assets:		
Deferred tax liabilities	117,956,750.00	67,562,000.00
Long-term equity investments	21,198,447,942.66	21,427,527,810.80
Other non-current financial assets	100,986,503.54	126,313,106.69
Other non-current assets	2,100,733,208.89	2,505,806,955.75
Fixed assets	7,291,387,236.53	7,083,251,505.14
Construction in progress	2,942,095,697.03	2,039,800,319.91
Right-of-use assets	433,996,758.51	—
Intangible assets	7,873,710,459.21	7,151,343,109.87
Goodwill	2,676,735,574.42	2,040,773,501.88
Long-term prepaid expenses	9,187,137,617.57	8,853,913,413.52
Long-term equity investments	114,180,385.70	95,198,631.30
Deferred tax liabilities	242,021,035.79	173,134,814.17
Other non-current liabilities	879,591,445.02	985,009,024.32
Total non-current liabilities	55,158,980,614.87	52,549,634,193.35
Total liabilities	78,569,297,725.65	70,551,361,387.48

Consolidated balance sheet (Continued)

30 September 2019

Items	30 September 2019	31 December 2018
Current liabilities:		
Short-term borrowings	7,440,018,220.78	5,607,192,955.63
Bills payable	266,942,486.20	149,003,072.96
Trade payables	2,233,670,981.77	2,184,280,272.14
Prepaid expenses	562,709,265.76	578,701,499.77
Transfer payables	451,969,450.66	478,905,270.26
Other payables	4,178,903,272.34	3,237,217,890.12
Interest payable: Interest on short-term borrowings	220,768,148.00	187,344,429.18
Dividends payable	139,956,011.68	125,420,505.60
Contract liabilities	388,047,456.85	530,896,724.79
Non-current liabilities: Long-term borrowings	2,206,056,772.37	4,929,603,365.34
Other non-current liabilities	1,599,149,293.47	227,445,337.32
Total non-current liabilities	19,327,467,200.20	17,923,246,388.33
Non-current liabilities:		
Long-term borrowings	8,816,140,333.28	8,630,661,547.43
Bills payable	5,781,204,728.90	4,039,456,986.21
Long-term payables	307,212,833.42	—
Long-term borrowings	252,679,111.96	416,889,805.19
Dividends payable	358,341,043.66	363,489,177.57
Dividends payable	2,895,818,060.31	2,908,359,008.27
Other non-current liabilities	2,878,227,018.69	2,676,545,098.82
Total non-current liabilities	21,289,623,130.22	19,035,401,623.49
Total non-current liabilities	40,617,090,330.42	36,958,648,011.82
Equity:		
Parent's equity (attributable to the parent)	2,562,898,545.00	2,563,060,895.00
Minority interest	11,918,086,638.94	10,544,648,359.54
Less: Treasury shares	—	1,711,169.00
Other comprehensive income	-238,833,703.62	-274,779,732.99
Surplus	2,373,685,050.45	2,374,999,312.51
Retained earnings	14,017,910,346.50	12,771,518,762.43
Total equity (attributable to the parent and minority interest)	30,633,746,877.27	27,977,736,427.49
Non-current liabilities	7,318,460,517.96	5,614,976,948.17
Total equity (attributable to the parent and minority interest)	37,952,207,395.23	33,592,713,375.66
Total liabilities and equity (attributable to the parent and minority interest)	78,569,297,725.65	70,551,361,387.48

Legal Representative:
Chen Qiyu

Chief Financial Officer:
Guan Xiaohui

Deputy Chief Accounting Officer:
Chen Zhanyu

Balance Sheet of the Parent Company

30 September 2019

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Unit: RMB Tenthousand Yuan

Items	30 September 2019	31 December 2018
Current assets:		
Cash and cash equivalents	1,106,498,344.52	850,102,168.54
Financial assets		
Prepaid expenses		
Other receivables	6,407,634,690.21	6,914,735,852.92
Inventory	299,410,098.84	230,691,574.83
Due from subsidiaries	354,609,680.05	307,409,680.05
Intangible assets	—	—
Non-current financial assets	2,536,000,000.00	1,625,000,000.00
Other non-current assets	239,000,000.00	158,570,000.00
Total current assets	10,289,133,034.73	9,548,408,021.46
Non-current assets:		
Due to subsidiaries	6,011,804,080.60	5,465,151,645.71
Long-term equity investments	23,961,991,164.92	22,999,277,541.00
Other non-current financial assets	37,689,534.30	37,626,487.24
Other non-current assets	147,179,403.98	184,188,803.45
Fixed assets	6,217,807.54	7,158,298.77
Construction in progress	2,305,418.41	2,305,418.41
Intangible assets	1,398,139.68	1,840,272.04
Deferred tax assets		
Goodwill		
Long-term liabilities		
Deferred tax liabilities		
Total non-current assets	30,168,585,549.43	28,697,548,466.62
Total assets	40,457,718,584.16	38,245,956,488.08

Balance Sheet of the Parent Company (Continued)

30 September 2019

Items	30 September 2019	31 December 2018
Current liabilities:		
Short-term borrowings	3,825,000,000.00	2,959,000,000.00
Bills payable		
Notes payable		
Accounts payable		
Prepaid expenses		
Other payables	94,480,035.63	124,637,901.93
Transfer payables	25,239,506.72	43,694,651.68
Other current liabilities	1,715,449,403.09	1,357,247,173.94
Liabilities due to subsidiaries	213,542,735.45	172,658,261.16
Dividends payable	229,468.00	229,468.00
Non-current liabilities	1,267,088,795.71	3,769,010,861.94
Other non-current liabilities	1,304,675,980.01	5,313,103.87
Long-term payables	8,231,933,721.16	8,258,903,693.36
Non-current liabilities:		
Long-term borrowings	346,740,000.00	66,740,000.00
Bills payable	5,781,204,728.90	4,039,456,986.21
Long-term payables		
Deferred income	325,000.00	550,000.00
Deferred liabilities	1,151,018,873.79	1,151,018,873.79
Other non-current liabilities		
Long-term payables	7,279,288,602.69	5,257,765,860.00
Long-term payables	15,511,222,323.85	13,516,669,553.36
Equity:		
Parent's equity (RMB)	2,562,898,545.00	2,563,060,895.00
Capital	14,247,927,508.28	14,231,054,756.04
Less: Treasury shares	—	1,711,169.00
Other equity	-327,370,661.53	-279,100,142.24
Shareholders' equity	1,247,565,522.50	1,247,565,522.50
Minority interest	7,215,475,346.06	6,968,417,072.42
Total (RMB)	24,946,496,260.31	24,729,286,934.72
Total (RMB)	40,457,718,584.16	38,245,956,488.08

Legal Representative:
Chen Qiyu

Chief Financial Officer:
Guan Xiaohui

Director of Accounting Department:
Chen Zhanyu

Ja, a y-Se e be 2019

January – September 2019

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Unit Price : RMB Total :

[illegible]

Consolidated Income Statement (Continued)

January – September 2019

Items	July – Sept 2019	July – Sept 2018	Jan – Sept 2019	Jan – Sept 2018
I. Operating Income	-9,016,755.16	-122,010,941.32	34,958,479.93	-532,197,468.31
Operating Income	7,142,372.12	-173,180,224.69	35,946,029.37	-571,964,925.72
() Operating Income	144,152.81	3,756,815.51	-26,694,169.11	-101,521,914.06
1. Operating Income	—	—	—	—
2. Operating Income	—	—	—	—
3. Operating Income	144,152.81	3,756,815.51	-26,694,169.11	-101,521,914.06
4. Operating Income	—	—	—	—
() Operating Income	6,998,219.31	-176,937,040.20	62,640,198.48	-470,443,011.66
1. Operating Income	-27,514,726.87	22,492,035.64	-57,540,529.80	29,149,580.97
2. Operating Income	34,512,946.18	-199,429,075.84	120,180,728.28	-499,592,592.63
Operating Income	-16,159,127.28	51,169,283.37	-987,549.44	39,767,457.41
II. Total Income	626,951,292.40	479,073,767.81	2,490,555,469.23	1,806,839,053.77
Total Income	554,726,673.16	360,501,362.79	2,099,650,177.36	1,522,187,428.09
Total Income	72,224,619.24	118,572,405.02	390,905,291.87	284,651,625.68
III. Earnings				
() Basic Earnings	0.22	0.20	0.81	0.83
() Diluted Earnings	0.22	0.20	0.81	0.83

Legal Representative:
Chen Qiyu

Chief Financial Officer:
Guan Xiaohui

Deputy Accounting Director:
Chen Zhanyu

Income Statement of the Parent Company

January – September 2019

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Unit: RMB Tenthousand Yuan

Items	July – Sept 2019	July – Sept 2018	Jan – Sept 2019	Jan – Sept 2018
I. Operating income	3,815,974.06	—	5,685,313.69	9,433.96
Less: Operating expenses	—	—	—	—
Transportation expenses	1,138,885.77	—	2,411,699.94	43,754.06
Sales and distribution expenses	—	—	—	—
General and administrative expenses	65,458,328.69	72,278,881.00	136,505,943.90	151,588,516.01
Research expenses	1,400,270.20	—	2,952,245.60	—
Financial expenses	24,847,472.18	29,794,031.27	105,319,187.87	78,043,266.55
Interest income	143,806,935.92	120,916,769.27	411,681,720.73	331,017,960.01
Interest expense	110,395,009.96	101,566,901.47	300,636,180.35	266,631,390.40
Assets impairment losses	—	—	—	—
Credit impairment losses	—	—	—	—
Plus: Other income	110,486.49	75,000.00	300,849.09	225,000.00
Interest income (“—” for loss)	438,727,482.59	409,853,353.52	1,342,948,533.13	1,328,284,941.99
Interest income (“—” for loss)	430,736,612.25	389,199,792.25	1,250,403,969.29	1,156,577,651.49
General and administrative expenses (“—” for loss)	—	—	—	—
General and administrative expenses (“—” for loss)	-14,794,694.59	66,221,631.43	-36,067,868.78	90,531,856.25
General and administrative expenses (“—” for loss)	7,349.80	-886.58	7,349.80	-886.58
II. Operating income (“—” for loss)	335,021,641.51	374,076,186.10	1,065,685,099.62	1,189,374,809.00
Plus: Non-operating income	—	—	—	—
Less: Non-operating expenses	—	—	—	—
III. Total (“—” for loss)	335,021,641.51	374,076,186.10	1,065,685,099.62	1,189,374,809.00
Less: Income tax	—	—	—	—
IV. Net income (“—” for loss)	335,021,641.51	374,076,186.10	1,065,685,099.62	1,189,374,809.00
Net income (“—” for loss)	335,021,641.51	374,076,186.10	1,065,685,099.62	1,189,374,809.00
Net income (“—” for loss)	—	—	—	—



4.2 Information on adjustments to the initial implementation of financial statements at the beginning of the year for the initial implementation of New Financial Instruments Standards, New Income Standards and New Lease Standards

Consolidated balance sheet

: 1. 6. 2019 G. 11. 1. 2019: RMB

[illegible]

Items	31 December 2018	1 January 2019	Adjustment
Non-current liabilities:			
Long-term loans	8,630,661,547.43	8,630,661,547.43	
Borrowings	4,039,456,986.21	4,039,456,986.21	
Long-term payables	—	—	
Long-term liabilities	—	—	
Long-term borrowings	—	325,992,167.00	-325,992,167.00
Long-term payables	416,889,805.19	398,095,841.52	18,793,963.67
Debt	363,489,177.57	363,489,177.57	
Debt	2,908,359,008.27	2,908,359,008.27	
Other long-term liabilities	2,676,545,098.82	2,676,545,098.82	
Total non-current liabilities	19,035,401,623.49	19,342,599,826.82	-307,198,203.33
Total liabilities	36,958,648,011.82	37,348,299,890.45	-389,651,878.63
Equity (or shareholders' interests):			
Paid-up capital (RMB)	2,563,060,895.00	2,563,060,895.00	
Capital	10,544,648,359.54	10,544,648,359.54	
Less: Minority interests	1,711,169.00	1,711,169.00	
Other equity	-274,779,732.99	-274,779,732.99	
Shareholders' equity	2,374,999,312.51	2,374,999,312.51	
Equity	12,771,518,762.43	12,771,518,762.43	
Total equity	27,977,736,427.49	27,977,736,427.49	
Net assets	5,614,976,948.17	5,614,976,948.17	
Total equity (RMB)	33,592,713,375.66	33,592,713,375.66	
Total liabilities and equity (RMB)	70,551,361,387.48	70,941,013,266.11	-389,651,878.63

Equity (or shareholders' interests):

For 1 January 2019, the Group's Net Liabilities are shown in the MOF.

The Group's Net Liabilities are shown in the MOF for 2019. The Group's Net Liabilities are shown in the MOF for 2019.

Balance Sheet of the Parent Company

Unit: million RMB

Items	31 December 2018	1 January 2019	Adjustment
Current assets:			
Cash and cash equivalents	850,102,168.54	850,102,168.54	
Accounts receivable	6,914,735,852.92	6,914,735,852.92	
Inventory	230,691,574.83	230,691,574.83	
Due from subsidiaries	307,409,680.05	307,409,680.05	
Net financial assets	1,625,000,000.00	1,625,000,000.00	
Other receivables	158,570,000.00	158,570,000.00	
Prepaid expenses	9,548,408,021.46	9,548,408,021.46	
Non-current assets:			
Due from subsidiaries	5,465,151,645.71	5,465,151,645.71	
Long-term equity investments	22,999,277,541.00	22,999,277,541.00	
Other long-term assets	37,626,487.24	37,626,487.24	
Other non-current financial assets	184,188,803.45	184,188,803.45	
Fair value changes	7,158,298.77	7,158,298.77	
Current assets held for sale	2,305,418.41	2,305,418.41	
Intangible assets	1,840,272.04	1,840,272.04	
Deferred tax assets	28,697,548,466.62	28,697,548,466.62	
Other non-current assets	38,245,956,488.08	38,245,956,488.08	
Current liabilities:			
Accounts payable	2,959,000,000.00	2,959,000,000.00	
Prepaid liabilities	124,637,901.93	124,637,901.93	
Trade payables	43,694,651.68	43,694,651.68	
Other payables	1,357,247,173.94	1,357,247,173.94	
Due to subsidiaries	172,658,261.16	172,658,261.16	
Due to banks	229,468.00	229,468.00	
Net financial liabilities	3,769,010,861.94	3,769,010,861.94	
Other liabilities	5,313,103.87	5,313,103.87	
Deferred tax liabilities	8,258,903,693.36	8,258,903,693.36	

Items	31 December 2018	1 January 2019	Adjustment
Non-current liabilities:			
Long-term borrowings	66,740,000.00	66,740,000.00	
Borrowings due	4,039,456,986.21	4,039,456,986.21	
Interest payable	—	—	
Provisions	—	—	
Deferred income	550,000.00	550,000.00	
Deferred tax liabilities	1,151,018,873.79	1,151,018,873.79	
Trade payables	5,257,765,860.00	5,257,765,860.00	
Trade receivables	13,516,669,553.36	13,516,669,553.36	
Equity (including minority interests):			
Preference shares	2,563,060,895.00	2,563,060,895.00	
Common shares	14,231,054,756.04	14,231,054,756.04	
Losses attributable to shareholders	1,711,169.00	1,711,169.00	
Other comprehensive income	-279,100,142.24	-279,100,142.24	
Share-based payments	1,247,565,522.50	1,247,565,522.50	
Retained earnings	6,968,417,072.42	6,968,417,072.42	
Total (including minority interests)	24,729,286,934.72	24,729,286,934.72	
Total liabilities and equity (including minority interests)	38,245,956,488.08	38,245,956,488.08	

4.3 Explanation on retrospective adjustments to previous comparative data for the initial implementation of New Financial Instruments Standards and New Lease Standards

For 1 January 2019, the Group has applied the New Lease Standards retrospectively to the beginning of the reporting period.

In accordance with the requirements of the New Lease Standards, the Group has applied the Standards retrospectively to the beginning of the reporting period. The Group has applied the Standards to the beginning of the reporting period, 1 January 2019. The Group has applied the Standards to the beginning of the reporting period, 1 January 2019. The Group has applied the Standards to the beginning of the reporting period, 1 January 2019.

4.4 Audited report

The audit report is as follows: